Founding Angel · Stuttgart, Germany

Bridging Deep Industry Expertise & Early-Stage Ventures

Dr. Peter Haug brings over 20 years of senior management experience in the chemical and pharmaceutical industry to co-found and develop start-ups in Chemistry, Cleantech, Biotech & Life Sciences.

Chemistry Cleantech Biotech Pharma
5+
Start-ups Co-founded
20+
Years Industry Experience
50+
Corporate Deals
€1B+
Transaction Volume

More than an investor — a co-founder with operational depth

The Founding Angel model combines substantial industry know-how with entrepreneurial commitment. Peter Haug joins early-stage ventures as an active co-founder, contributing strategy, networks, business development and leadership — not just capital.

What makes a Founding Angel different?

A Founding Angel is not a passive investor or a pure mentor. He becomes a true co-founder: taking responsibility for specific functional areas, opening doors to industrial partners, customers and investors, and sharing the risk of the entrepreneurial journey.

This model is especially powerful in sectors that require deep technical and regulatory knowledge — Chemistry, Cleantech, Biotech & Life Sciences — where industry experience is a rare and decisive competitive advantage.

  • ⚗️Deep domain expertise across four sectors: Chemistry, Cleantech, Biotech & Life Sciences
  • 🤝Active co-founder role with specific functional responsibility (CFO, Head BD, CEO)
  • 🌐Extensive network of industrial partners, investors and research institutions
  • 📈Track record from start-up through Series A, crowdfunding and strategic exit

Industry Know-how

Senior management in CDMO, holding and specialty chemicals groups

Entrepreneurship

Co-founder in 5 ventures across chemistry, cleantech, biotech & pharma

Innovation Bridge

Connecting academic inventions with industrial markets and capital

Business Development

Partnerships, licensing, clinical validation and market entry strategy

Start-up Ventures

Five companies co-founded and developed across Chemistry, Cleantech, Biotech & Life Sciences — from initial concept through Series A funding, award-winning product launches and strategic exits.

noscendo – sepsis diagnostics
noscendo Life Science & Diagnostics

noscendo GmbH

Co-Founder · CFO · Head Business Development

Rapid molecular diagnostics for life-threatening infectious diseases. Next-generation sequencing of pathogen DNA from blood — results within hours instead of days.

Learn more
oncgnostics – cervical cancer diagnostics
oncgnostics Life Science & Diagnostics

oncgnostics GmbH

Co-Founder · Head Business Development

Epigenetics-based cervical cancer diagnostics. The GynTect® test detects aberrant DNA methylation patterns to identify cervical cancer with high specificity.

Learn more
Greasoline – biofuels from waste fats
Greasoline Cleantech & Energy

Greasoline GmbH

Co-Founder · CEO (Aug 2011 – Jun 2014)

Innovative process to convert waste cooking oil and animal fats into high-quality bio-jet fuel and other fuels — without transesterification and with higher yields.

Learn more
300Microns – 3D cell culture scaffolds
300Microns Biotech & Pharma

300Microns GmbH

Interim Manager · Advisory Board (2013–2015)

3D cell culture scaffolds for pharmaceutical research and drug development. Winner of the CyberForum Startup Award 2014.

Learn more
AViSpectro – Raman spectroscopy
AViSpectro Chemistry & Analytics

AViSpectro GmbH

Co-Founder · Business Development

Innovative Raman micro-spectroscopy technology for rapid, non-destructive analysis of surfaces and materials. Applications in quality control and research.

Learn more

Four Sectors. One Founding Angel.

Deep sectoral knowledge built over two decades in senior management positions — now deployed for start-up success.

Explore Expertise →

Press & Publications

Recent coverage from across the portfolio companies and thought leadership articles.

May 2022

noscendo closes Series B financing round

noscendo GmbH successfully closed a Series B financing round to advance its next-generation sequencing platform for rapid pathogen identification in critically ill patients.

noscendo press release
August 2022

oncgnostics licenses GynTect® to Chinese partner

oncgnostics GmbH signed a licensing agreement with a Chinese diagnostics company for the GynTect® cervical cancer test — opening access to one of the world's largest markets.

oncgnostics / 360Dx
September 2019

noscendo receives AWS start-up grant

The AWS (Austria Wirtschaftsservice) selected noscendo for its prestigious start-up grant, supporting further development of the DISQVER® diagnostic system for sepsis.

AWS / noscendo
All News →

Industry Roots — Corporate to Entrepreneurial

Two decades of senior management in the chemical and pharmaceutical industry form the foundation of the Founding Angel approach.

CDMO · ~1,500 employees · €250M revenue
Senior VP Operations & Corporate Development

Strategic and operational leadership across multiple production sites for a leading European contract development and manufacturing organisation.

Chemical Holding · ~3,000 employees · €700M revenue
VP Corporate Development & Strategy

Group-level strategy, M&A, and new business development across a diversified specialty chemicals holding company.

Laboratory analytics
Dr. Peter Haug
PhD Chemistry · Stuttgart · 20+ years industry experience